Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Rigby MR, et al. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23. Lancet Diabetes Endocrinol. 2013. PMID: 24622414 Free PMC article. Clinical Trial.
Targeting memory T cells in type 1 diabetes.
Ehlers MR, Rigby MR. Ehlers MR, et al. Among authors: rigby mr. Curr Diab Rep. 2015 Nov;15(11):84. doi: 10.1007/s11892-015-0659-5. Curr Diab Rep. 2015. PMID: 26370695 Review.
Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.
Pinckney A, Rigby MR, Keyes-Elstein L, Soppe CL, Nepom GT, Ehlers MR. Pinckney A, et al. Among authors: rigby mr. Clin Ther. 2016 Jun;38(6):1327-1339. doi: 10.1016/j.clinthera.2016.04.032. Epub 2016 May 18. Clin Ther. 2016. PMID: 27209482 Free PMC article. Clinical Trial.
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR; START Study Team. Gitelman SE, et al. Among authors: rigby mr. Lancet Diabetes Endocrinol. 2013 Dec;1(4):306-16. doi: 10.1016/S2213-8587(13)70065-2. Epub 2013 Aug 28. Lancet Diabetes Endocrinol. 2013. PMID: 24622416 Free PMC article. Clinical Trial.
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Rigby MR, et al. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20. J Clin Invest. 2015. PMID: 26193635 Free PMC article. Clinical Trial.
Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, Leu JH, Zoka R, Hedrick JA, Rigby MR, Vercruysse F; T1GER Study Investigators. Quattrin T, et al. Among authors: rigby mr. N Engl J Med. 2020 Nov 19;383(21):2007-2017. doi: 10.1056/NEJMoa2006136. N Engl J Med. 2020. PMID: 33207093 Clinical Trial.
Neuroendocrine dysfunction in pediatric critical illness.
Hebbar K, Rigby MR, Felner EI, Easley KA, Fortenberry JD. Hebbar K, et al. Among authors: rigby mr. Pediatr Crit Care Med. 2009 Jan;10(1):35-40. doi: 10.1097/PCC.0b013e3181936ef3. Pediatr Crit Care Med. 2009. PMID: 19057442
63 results